BioInvent and Servier ink oncology collaboration

Sweden’s BioInvent International (OMXS: BINV) and independent French drugmaker Laboratoires Servier have entered into an antibody collaboration on an oncology target involved in tumor cell metabolism provided by Servier.

Under the terms of the accord, BioInvent will receive a licensing fee, research support and potential milestone payments of more than 11 million euros ($14 million), as well as royalty on future sales of the product.

The accord means Servier will engage BioInvent to screen its proprietary n-CoDeR library for antibodies specific to the undisclosed target. Servier will also have access to BioInvent's in-house preclinical capacities in selecting an antibody candidate for development.